BETHLEHEM, Pa., May 13 /PRNewswire/ -- Particle Sciences has expanded its production capacity by the addition of a 500 sq ft Class 1000 (ISO 6) clean room. The space also contains several Class 100 hoods for sterile work. The space was added to the existing 15,000 sq ft facility in response to the increasing need for clinical trial material manufacturing, especially that of semisolids, suspensions and dispersions. “This investment is the latest in a series of acquisitions aimed at streamlining our client’s drug development process by increasing our capacity,” says Andrew Loxley, Director of New Technology at the company. “By providing a complete suite of drug development services from preformulation though CTM manufacture, our clients are able to more efficiently manage their drug product development efforts through a single supplier.”
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
Contact: Maureen Cochran 610-861-4701
CONTACT: Maureen Cochran of Particle Sciences, +1-610-861-4701
Web site: http://www.particlesciences.com/
